A Phase Ib Study of SGN-40 in Combination With Rituximab and Gemcitabine for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine the safety and adverse-event profile for combination therapy of SGN-40 with gemcitabine and rituximab.
10 months from registration of last patient
Yes
Nancy Whiting, PharmD
Study Director
Seattle Genetics, Inc.
United States: Food and Drug Administration
SG040-0008
NCT00655837
April 2008
February 2010
Name | Location |
---|---|
Memorial Sloan Kettering Cancer Center | New York, New York 10021 |
Washington University School of Medicine | Saint Louis, Missouri 63110 |
University of Colorado | Denver, Colorado 80217 |
University of Alabama at Birmingham | Birmingham, Alabama 35294-3300 |
University of Pennsylvania | Philadelphia, Pennsylvania 19104 |
Duke University Medical Center | Durham, North Carolina 27710 |
Nevada Cancer Institute | Las Vegas, Nevada 89135 |
Mayo Clinic Arizona | Scottsdale, Arizona 85259 |
Oncology Specialists | Park Ridge, Illinois 60068 |